mixiu personal page - To The Moon

mixiu

mixiu

No personal profile

8Follow

2Followers

0Topic

0Badge

2022-02-08

👍🏻

Sorry, the original content has been removed

2022-01-31

Great ariticle, would you like to share it?

@TigerEvents:Join Tiger Ski Championship, Win a Bonus of Up to USD 2022

2022-01-31

👍🏻

Sorry, the original content has been removed

2021-12-31

👍🏻

What Will It Take for Space Stocks to Win Over Investors in 2022?

2021-06-15

Gooooo

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

2021-06-15

$Velodyne Lidar Inc(VLDR)$persist

2021-06-14

$Bionano Genomics(BNGO)$time to go past 8..

2021-06-11

$Bionano Genomics(BNGO)$go up somemore please ^^

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581894265427467","uuid":"3581894265427467","gmtCreate":1618800987302,"gmtModify":1706620740510,"name":"mixiu","pinyin":"mixiu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":8,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.99%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9096107100,"gmtCreate":1644323109821,"gmtModify":1676533912263,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096107100","repostId":"1147872057","repostType":4,"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9093679317,"gmtCreate":1643624350920,"gmtModify":1676533837367,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093679317","repostId":"9004448317","repostType":1,"repost":{"id":9004448317,"gmtCreate":1642676525258,"gmtModify":1676533734534,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"Join Tiger Ski Championship, Win a Bonus of Up to USD 2022","htmlText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","listText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","text":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: Click to Join the Game","images":[{"img":"https://static.tigerbbs.com/a7b44fa056439fb4010fa55e163d27c3","width":"750","height":"1726"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004448317","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9093670719,"gmtCreate":1643624208753,"gmtModify":1676533837351,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093670719","repostId":"1174547672","repostType":2,"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003365640,"gmtCreate":1640880654708,"gmtModify":1676533550850,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003365640","repostId":"1194228505","repostType":4,"repost":{"id":"1194228505","kind":"news","pubTimestamp":1640878332,"share":"https://ttm.financial/m/news/1194228505?lang=&edition=fundamental","pubTime":"2021-12-30 23:32","market":"us","language":"en","title":"What Will It Take for Space Stocks to Win Over Investors in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1194228505","media":"Bloomberg","summary":"Thin rosters of public companies turn in lukewarm 2021 returnsTourism flights aren’t enough to prove","content":"<html><head></head><body><ul><li>Thin rosters of public companies turn in lukewarm 2021 returns</li><li>Tourism flights aren’t enough to prove it’s a real industry</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a8140cdf7af3ca86cfd68c78da5aa66f\" tg-width=\"2000\" tg-height=\"1501\" referrerpolicy=\"no-referrer\"/><span>Elon Musk Photographer: Liesa Johannssen-Koppitz/Bloomberg</span></p><p>Space stocks fizzled this past year despite their futuristic lure. Some Elon Musk-style boosterism, similar to what he did for the electric vehicle industry, might be just what they need to stage a 2022 turnaround.</p><p>Musk has floated the idea of taking his SpaceX company public, and the parallel with EVs would be hard to ignore. Space exploration and electric vehicles both focus on a future that isn’t quite here yet, promising massive opportunities as new technologies evolve into viable companies.</p><p>But while stocks tied to the EV revolution soared this year, space-focused names -- after some initial euphoria -- badly trailed the broad market. High-profile tourist flights by Richard Branson’s publicly traded Virgin Galactic Holdings Inc., and by Jeff Bezos’s privately held Blue Origin and Musk’s SpaceX, weren’t enough to overcome doubts about whether this is a real business or just a divertissement for billionaires.</p><p><img src=\"https://static.tigerbbs.com/6016014c69a52502ab88d7ca1d3bb8db\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"/></p><p>“From commercial space launches related to satellites and space tourism, or even more futuristic things like asteroid mining -- a lot of it is a completely unproven industry, and it is not clear how much demand there is,” said Jay Jacobs, head of research and strategy at Global X Management Co. What’s more, there aren’t many pure-play public companies apart from Virgin Galactic, said Jacobs, whose firm manages exchange-traded funds but hasn’t started one for space.</p><p>This leaves the space sector without a clear front-runner or milestones that could help public investors judge progress. It doesn’t help that the companies trading on exchanges lack a charismatic cheerleader to focus the market’s attention. If Musk’s Space Exploration Technologies Corp. chooses to go public, that would solve some of those issues all at once.</p><p>“It would be a tent-pole IPO,” said Nicholas Colas, co-founder of DataTrek Research. “It is that single asset that can focus people’s attention and make them understand what is space investing about. It isn’t about going to Mars or tourism, but getting hardware to space that is current, updated technology.”</p><p>SpaceX didn’t respond to a request for comment.</p><p>Musk is often credited with leading the automotive industry toward an electric future. It was only after Tesla Inc.’s runaway success last year -- both as a company and as a stock -- that other EV names really started garnering attention. Musk could do the same for space stocks, according to Andrew Chanin, chief executive of ProcureAM, which manages a space ETF.</p><p><b>Flying Blind</b></p><p>“When you see a company worth half a trillion dollars entering the markets, that is bound to get attract some attention for other stocks in that market,” Chanin said. “There is still a public misconception of what space is, how space affects us, and there is this massive educational curve that we still haven’t seen investors truly grasp.”</p><p>Musk has been stirring the pot in Musk-like fashion, musing about turning carbon dioxide into spacecraft fuel, building massive rockets,going to Mars within a decade and the potential for bankruptcy in almost the same breath. </p><p>Space tourism flights drew an outsized amount of news coverage, even though they just scratch the surface of the industry, Chanin said. The future promises commercial uses that could include applications in military and defense, telecommunications, mining, weather tracking and deep space exploration.</p><p>For now, though, starry-eyed investors have been stuck in low orbit, and sometimes in a black hole. The Procure Space ETF -- which trades under the ticker UFO-- has gained just 6% for 2021, far behind the 28% jump in the S&amp;P 500 Index.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/73b58e74acb6e3cae53d75758f9bdf4b\" tg-width=\"2200\" tg-height=\"1467\" referrerpolicy=\"no-referrer\"/><span>Richard Branson’s Virgin Galactic was one of the earlier space-focused companies to go public.Photographer: Drew Angerer/Getty Images</span></p><p>Virgin Galactic tumbled 45% amid multiple delays to the start of commercial launches. Analysts collectively don’t expect an annual net profit for the company in the next three years. At satellite launch services provider Astra Space Inc.(down 35%) and space-based data and analytics company Spire Global Inc.(down 66%), analysts estimate their first annual profit will come around 2024.</p><p>Still, riding the first stages has its advantages, as many early Tesla or Bitcoin investors would vouch.</p><p>“You can think of space stocks in the last two years as kind of the dotcom bubble,” said DataTrek’s Colas. “There is an initial burst of enthusiasm, then interest dies off and then a couple years later you realize that maybe a lot of the seeds died but the ones that survived have become systemically important.”</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Will It Take for Space Stocks to Win Over Investors in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Will It Take for Space Stocks to Win Over Investors in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 23:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-30/space-stocks-need-an-elon-musk-booster-to-win-over-investors?srnd=premium><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thin rosters of public companies turn in lukewarm 2021 returnsTourism flights aren’t enough to prove it’s a real industryElon Musk Photographer: Liesa Johannssen-Koppitz/BloombergSpace stocks fizzled ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-30/space-stocks-need-an-elon-musk-booster-to-win-over-investors?srnd=premium\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","ASTR":"Astra Space","SPIR":"Spire Global Inc.","SPCE":"维珍银河","UFO":"Procure Space ETF"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-30/space-stocks-need-an-elon-musk-booster-to-win-over-investors?srnd=premium","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194228505","content_text":"Thin rosters of public companies turn in lukewarm 2021 returnsTourism flights aren’t enough to prove it’s a real industryElon Musk Photographer: Liesa Johannssen-Koppitz/BloombergSpace stocks fizzled this past year despite their futuristic lure. Some Elon Musk-style boosterism, similar to what he did for the electric vehicle industry, might be just what they need to stage a 2022 turnaround.Musk has floated the idea of taking his SpaceX company public, and the parallel with EVs would be hard to ignore. Space exploration and electric vehicles both focus on a future that isn’t quite here yet, promising massive opportunities as new technologies evolve into viable companies.But while stocks tied to the EV revolution soared this year, space-focused names -- after some initial euphoria -- badly trailed the broad market. High-profile tourist flights by Richard Branson’s publicly traded Virgin Galactic Holdings Inc., and by Jeff Bezos’s privately held Blue Origin and Musk’s SpaceX, weren’t enough to overcome doubts about whether this is a real business or just a divertissement for billionaires.“From commercial space launches related to satellites and space tourism, or even more futuristic things like asteroid mining -- a lot of it is a completely unproven industry, and it is not clear how much demand there is,” said Jay Jacobs, head of research and strategy at Global X Management Co. What’s more, there aren’t many pure-play public companies apart from Virgin Galactic, said Jacobs, whose firm manages exchange-traded funds but hasn’t started one for space.This leaves the space sector without a clear front-runner or milestones that could help public investors judge progress. It doesn’t help that the companies trading on exchanges lack a charismatic cheerleader to focus the market’s attention. If Musk’s Space Exploration Technologies Corp. chooses to go public, that would solve some of those issues all at once.“It would be a tent-pole IPO,” said Nicholas Colas, co-founder of DataTrek Research. “It is that single asset that can focus people’s attention and make them understand what is space investing about. It isn’t about going to Mars or tourism, but getting hardware to space that is current, updated technology.”SpaceX didn’t respond to a request for comment.Musk is often credited with leading the automotive industry toward an electric future. It was only after Tesla Inc.’s runaway success last year -- both as a company and as a stock -- that other EV names really started garnering attention. Musk could do the same for space stocks, according to Andrew Chanin, chief executive of ProcureAM, which manages a space ETF.Flying Blind“When you see a company worth half a trillion dollars entering the markets, that is bound to get attract some attention for other stocks in that market,” Chanin said. “There is still a public misconception of what space is, how space affects us, and there is this massive educational curve that we still haven’t seen investors truly grasp.”Musk has been stirring the pot in Musk-like fashion, musing about turning carbon dioxide into spacecraft fuel, building massive rockets,going to Mars within a decade and the potential for bankruptcy in almost the same breath. Space tourism flights drew an outsized amount of news coverage, even though they just scratch the surface of the industry, Chanin said. The future promises commercial uses that could include applications in military and defense, telecommunications, mining, weather tracking and deep space exploration.For now, though, starry-eyed investors have been stuck in low orbit, and sometimes in a black hole. The Procure Space ETF -- which trades under the ticker UFO-- has gained just 6% for 2021, far behind the 28% jump in the S&P 500 Index.Richard Branson’s Virgin Galactic was one of the earlier space-focused companies to go public.Photographer: Drew Angerer/Getty ImagesVirgin Galactic tumbled 45% amid multiple delays to the start of commercial launches. Analysts collectively don’t expect an annual net profit for the company in the next three years. At satellite launch services provider Astra Space Inc.(down 35%) and space-based data and analytics company Spire Global Inc.(down 66%), analysts estimate their first annual profit will come around 2024.Still, riding the first stages has its advantages, as many early Tesla or Bitcoin investors would vouch.“You can think of space stocks in the last two years as kind of the dotcom bubble,” said DataTrek’s Colas. “There is an initial burst of enthusiasm, then interest dies off and then a couple years later you realize that maybe a lot of the seeds died but the ones that survived have become systemically important.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187515920,"gmtCreate":1623758711260,"gmtModify":1703818329252,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"Gooooo","listText":"Gooooo","text":"Gooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/187515920","repostId":"1178091722","repostType":2,"repost":{"id":"1178091722","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187129844,"gmtCreate":1623747281088,"gmtModify":1704210253699,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VLDR\">$Velodyne Lidar Inc(VLDR)$</a>persist","listText":"<a href=\"https://laohu8.com/S/VLDR\">$Velodyne Lidar Inc(VLDR)$</a>persist","text":"$Velodyne Lidar Inc(VLDR)$persist","images":[{"img":"https://static.tigerbbs.com/0aa1d553cb1015fd19e34031572da079","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/187129844","isVote":1,"tweetType":1,"viewCount":685,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":185554750,"gmtCreate":1623662315670,"gmtModify":1704208068014,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>time to go past 8..","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>time to go past 8..","text":"$Bionano Genomics(BNGO)$time to go past 8..","images":[{"img":"https://static.tigerbbs.com/29b2091eb12478e1527fe3b7d42d5aac","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185554750","isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181595751,"gmtCreate":1623400364973,"gmtModify":1704202577352,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>go up somemore please ^^","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>go up somemore please ^^","text":"$Bionano Genomics(BNGO)$go up somemore please ^^","images":[{"img":"https://static.tigerbbs.com/7c40112bb36e2883421d4da67d0d838c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181595751","isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":181595751,"gmtCreate":1623400364973,"gmtModify":1704202577352,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>go up somemore please ^^","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>go up somemore please ^^","text":"$Bionano Genomics(BNGO)$go up somemore please ^^","images":[{"img":"https://static.tigerbbs.com/7c40112bb36e2883421d4da67d0d838c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181595751","isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9003365640,"gmtCreate":1640880654708,"gmtModify":1676533550850,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003365640","repostId":"1194228505","repostType":4,"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187129844,"gmtCreate":1623747281088,"gmtModify":1704210253699,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VLDR\">$Velodyne Lidar Inc(VLDR)$</a>persist","listText":"<a href=\"https://laohu8.com/S/VLDR\">$Velodyne Lidar Inc(VLDR)$</a>persist","text":"$Velodyne Lidar Inc(VLDR)$persist","images":[{"img":"https://static.tigerbbs.com/0aa1d553cb1015fd19e34031572da079","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/187129844","isVote":1,"tweetType":1,"viewCount":685,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9096107100,"gmtCreate":1644323109821,"gmtModify":1676533912263,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096107100","repostId":"1147872057","repostType":4,"repost":{"id":"1147872057","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644322035,"share":"https://ttm.financial/m/news/1147872057?lang=&edition=fundamental","pubTime":"2022-02-08 20:07","market":"us","language":"en","title":"Vaccine Stocks Slipped in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1147872057","media":"Tiger Newspress","summary":"Vaccine stocks slipped in premarket trading, with Novavax down 6.23% and Moderna down 2.41%.Novavax ","content":"<html><head></head><body><p>Vaccine stocks slipped in premarket trading, with Novavax down 6.23% and Moderna down 2.41%.<img src=\"https://static.tigerbbs.com/e6107eb27d788a321cd9ac7f79015488\" tg-width=\"377\" tg-height=\"287\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax Inc</a> has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government&#39;s vaccine rollouts told Reuters.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slipped in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slipped in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-08 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks slipped in premarket trading, with Novavax down 6.23% and Moderna down 2.41%.<img src=\"https://static.tigerbbs.com/e6107eb27d788a321cd9ac7f79015488\" tg-width=\"377\" tg-height=\"287\" referrerpolicy=\"no-referrer\"/><a href=\"https://laohu8.com/S/NVAX\">Novavax Inc</a> has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government&#39;s vaccine rollouts told Reuters.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147872057","content_text":"Vaccine stocks slipped in premarket trading, with Novavax down 6.23% and Moderna down 2.41%.Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government's vaccine rollouts told Reuters.","news_type":1},"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187515920,"gmtCreate":1623758711260,"gmtModify":1703818329252,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"Gooooo","listText":"Gooooo","text":"Gooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/187515920","repostId":"1178091722","repostType":2,"repost":{"id":"1178091722","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185554750,"gmtCreate":1623662315670,"gmtModify":1704208068014,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>time to go past 8..","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>time to go past 8..","text":"$Bionano Genomics(BNGO)$time to go past 8..","images":[{"img":"https://static.tigerbbs.com/29b2091eb12478e1527fe3b7d42d5aac","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185554750","isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9093679317,"gmtCreate":1643624350920,"gmtModify":1676533837367,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093679317","repostId":"9004448317","repostType":1,"repost":{"id":9004448317,"gmtCreate":1642676525258,"gmtModify":1676533734534,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"Join Tiger Ski Championship, Win a Bonus of Up to USD 2022","htmlText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","listText":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: <a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/happy-new-year/#/\" target=\"_blank\">Click to Join the Game</a>","text":"2022 is the Year of Tiger in Chinese lunar calendar, it’s also a special year for Tiger Brokers. To celebrate the special year, we want to invite you to join the ski game presented by Tiger Brokers specially, and it’s very easy and interesting game for users to play. Join the game and win a bonus of up to USD 2022 and limited-edition Tiger Toys Spring Festival and Winter Olympic are both on the way, open your Tiger Trade App and play the ski game with us, win golden medals as many as you can! You could have chance to try Lucky Draw when you win medals.The more medal you win, the bigger bonus you may win! Big Rewards are as follow: Click to Join the Game","images":[{"img":"https://static.tigerbbs.com/a7b44fa056439fb4010fa55e163d27c3","width":"750","height":"1726"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004448317","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9093670719,"gmtCreate":1643624208753,"gmtModify":1676533837351,"author":{"id":"3581894265427467","authorId":"3581894265427467","name":"mixiu","avatar":"https://static.tigerbbs.com/8770b9d55952a120013f9f3540bb780e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581894265427467","authorIdStr":"3581894265427467"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093670719","repostId":"1174547672","repostType":2,"repost":{"id":"1174547672","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643620856,"share":"https://ttm.financial/m/news/1174547672?lang=&edition=fundamental","pubTime":"2022-01-31 17:20","market":"us","language":"zh","title":"盘前异动 | 中概股涨势汹汹，纳指期货企稳走高","url":"https://stock-news.laohu8.com/highlight/detail?id=1174547672","media":"老虎资讯综合","summary":"1月31日，美股股指期货小幅走高，道指期货涨0.02%，纳指期货涨0.72%，标普500指数涨0.23%。美股科技股盘前多数上涨，特斯拉、英伟达、AMD、阿斯麦涨超2%，奈飞涨近2%，苹果涨近1%；热","content":"<html><head></head><body><p>1月31日，美股股指期货小幅走高，道指期货涨0.02%，纳指期货涨0.72%，标普500指数涨0.23%。</p><p><img src=\"https://static.tigerbbs.com/1d58b0bdc86c6fa386722b9e202ed6b5\" tg-width=\"385\" tg-height=\"188\" referrerpolicy=\"no-referrer\"/></p><p>美股科技股盘前多数上涨，<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>、<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>、<a href=\"https://laohu8.com/S/AMD\">AMD</a>、<a href=\"https://laohu8.com/S/ASML\">阿斯麦</a>涨超2%，<a href=\"https://laohu8.com/S/NFLX\">奈飞</a>涨近2%，<a href=\"https://laohu8.com/S/AAPL\">苹果</a>涨近1%；</p><p>热门中概股盘前多数走高，<a href=\"https://laohu8.com/S/IQ\">爱奇艺</a>涨超4%，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>、<a href=\"https://laohu8.com/S/JD\">京东</a>、<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>、<a href=\"https://laohu8.com/S/BEKE\">贝壳</a>、<a href=\"https://laohu8.com/S/WB\">微博</a>涨超3%，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>、<a href=\"https://laohu8.com/S/LI\">理想汽车</a>、<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>、<a href=\"https://laohu8.com/S/DIDI\">滴滴</a>涨超2%；</p><p><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯医药</a>盘前涨超8%，此前消息，与以色列达成协议，提供500万剂新冠肺炎疫苗。</p><p><a href=\"https://laohu8.com/S/BYND\">Beyond Meat</a>盘前涨超5%，巴克莱将其从减配上调到超配，目标价从70美元上调至80美元。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>盘前异动 | 中概股涨势汹汹，纳指期货企稳走高</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n盘前异动 | 中概股涨势汹汹，纳指期货企稳走高\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2022-01-31 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>1月31日，美股股指期货小幅走高，道指期货涨0.02%，纳指期货涨0.72%，标普500指数涨0.23%。</p><p><img src=\"https://static.tigerbbs.com/1d58b0bdc86c6fa386722b9e202ed6b5\" tg-width=\"385\" tg-height=\"188\" referrerpolicy=\"no-referrer\"/></p><p>美股科技股盘前多数上涨，<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>、<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>、<a href=\"https://laohu8.com/S/AMD\">AMD</a>、<a href=\"https://laohu8.com/S/ASML\">阿斯麦</a>涨超2%，<a href=\"https://laohu8.com/S/NFLX\">奈飞</a>涨近2%，<a href=\"https://laohu8.com/S/AAPL\">苹果</a>涨近1%；</p><p>热门中概股盘前多数走高，<a href=\"https://laohu8.com/S/IQ\">爱奇艺</a>涨超4%，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>、<a href=\"https://laohu8.com/S/JD\">京东</a>、<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>、<a href=\"https://laohu8.com/S/BEKE\">贝壳</a>、<a href=\"https://laohu8.com/S/WB\">微博</a>涨超3%，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>、<a href=\"https://laohu8.com/S/LI\">理想汽车</a>、<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>、<a href=\"https://laohu8.com/S/DIDI\">滴滴</a>涨超2%；</p><p><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯医药</a>盘前涨超8%，此前消息，与以色列达成协议，提供500万剂新冠肺炎疫苗。</p><p><a href=\"https://laohu8.com/S/BYND\">Beyond Meat</a>盘前涨超5%，巴克莱将其从减配上调到超配，目标价从70美元上调至80美元。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174547672","content_text":"1月31日，美股股指期货小幅走高，道指期货涨0.02%，纳指期货涨0.72%，标普500指数涨0.23%。美股科技股盘前多数上涨，特斯拉、英伟达、AMD、阿斯麦涨超2%，奈飞涨近2%，苹果涨近1%；热门中概股盘前多数走高，爱奇艺涨超4%，拼多多、京东、哔哩哔哩、贝壳、微博涨超3%，蔚来、理想汽车、小鹏汽车、滴滴涨超2%；诺瓦瓦克斯医药盘前涨超8%，此前消息，与以色列达成协议，提供500万剂新冠肺炎疫苗。Beyond Meat盘前涨超5%，巴克莱将其从减配上调到超配，目标价从70美元上调至80美元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}